CorMedix Inc., a Berkeley Heights-based biopharmaceutical firm, announced on Monday it has appointed Matt David as its executive vice president and chief financial officer.
“I am pleased that Matt has agreed to join the company at this most exciting time,” CorMedix CEO Khoso Baluch said. “With his medical background and his significant experience in health care capital markets and strategy, he will fill an important role as we continue our preparations to commercialize Neutrolin (an investigational drug product), whether on our own or with a strategic or commercial partner.”
CorMedix focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
Before CorMedix, David was head of strategy at Ovid Therapeutics. He also has more than 15 years of experience in health care finance.
“I am thrilled to be joining CorMedix at such an exciting time for the company,” David. “As Neutrolin approaches a potential regulatory approval later this year, the company will face a range of strategic decisions all aimed at bringing Neutrolin to patients who can benefit from it as expeditiously as possible. I am excited by the prospects of this novel product in the substantial hemodialysis market and look forward to working with the broader CorMedix team.”
